Under earlier rules, drugmakers had to get a test licence from CDSCO to manufacture small quantities of drugs for research, ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, ...

The inflation-adjusted cost of developing a new drug now doubles roughly every nine years. To reverse this trend, the ...

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine New antiviral drugs in development could offer the ...

Medicare will negotiate prices for Part B injectable drugs for the first time, aiming to lower costs for millions of patients ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Two formative experiences shaped Craig Crews’ path into drug development. First, when he was still a child, his grandmother died from cancer at just 52 years old. “At the time, there weren’t very many ...

Cambridge’s Kendall Square bills itself as “the most innovative square mile on the planet” — but it’s possible that less of that innovation is happening in Cambridge as life science firms outsource ...